Annette Werger,Carlos Rodriguez-Galindo,Katherine A Janeway,Prasanna Ananth,Stephan Voss
Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee.,Department of Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.,Department of Radiology, Boston Children's Hospital, Boston, Massachusetts.
Publication
Summary
Efficacy of liposomal doxorubicin (LD) in treating desmoid fibromatosis (DF) in children has not been well evaluated. This retrospective case series examines five children with progressive DF, treated with LD. We report progression-free intervals (PFIs) and radiographic as well as clinical responses for each medication received. LD was well tolerated, with an average 4.5% reduction in tumor size and median PFI of 29 months. Treatment with LD conferred the longest PFI of all medical therapies pursued. Thus, LD is an important treatment option for DF in pediatrics.
Stay Up to Date as We Uncover More About Desmoid Tumors
